| Followers | 28 |
| Posts | 21619 |
| Boards Moderated | 0 |
| Alias Born | 01/16/2026 |
Monday, April 06, 2026 4:00:18 AM
ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX
April 6, 2026 3:55 AM
PR Newswire (US)
LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of IBRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: January 19, 2026 to March 24, 2026
DEADLINE: May 26, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. ImmunityBio materially misstated the capabilities of its Anktiva medication. Based on these facts, ImmunityBio's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: David@djslawllp.com
View original content:https://www.prnewswire.com/news-releases/immunitybio-inc-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--ibrx-302734444.html
SOURCE DJS Law Group LLP
Recent IBRX News
- The $13 Million Company Teaching the Immune System to Hunt Cancer • PR Newswire (Canada) • 05/29/2026 01:00:00 PM
- The $13 Million Company Teaching the Immune System to Hunt Cancer • PR Newswire (US) • 05/29/2026 01:00:00 PM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX • PR Newswire (US) • 05/26/2026 01:00:00 PM
- ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS • Business Wire • 05/22/2026 11:30:00 AM
- ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation • Business Wire • 05/22/2026 11:30:00 AM
- ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027 • Business Wire • 05/20/2026 12:30:00 AM
- Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 05/19/2026 01:00:00 PM
- Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes • PR Newswire (US) • 05/19/2026 01:00:00 PM
- Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes • PR Newswire (Canada) • 05/19/2026 01:00:00 PM
- ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026 • Business Wire • 05/19/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/18/2026 09:20:47 PM
- ImmunityBio Shares Rise After Securing Five New U.S. Patents for Bladder Cancer Therapy (IBRX) • IH Market News • 05/18/2026 02:35:29 PM
- ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035 • Business Wire • 05/18/2026 11:30:00 AM
- ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States • Business Wire • 05/16/2026 05:35:00 PM
- ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX • PR Newswire (US) • 05/14/2026 07:23:00 AM
- Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 05/12/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:32:40 AM
- ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million • Business Wire • 05/07/2026 11:30:00 AM
- ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting • Business Wire • 05/05/2026 11:30:00 AM
- IBRX Lawsuit Alleges Chairman Allegedly Overstated Drug Capabilities - ImmunityBio Investors Face Losses Following Chairman Allegedly Overstated Drug Capabilities: SueWallSt • PR Newswire (US) • 04/30/2026 01:00:00 PM
- IBRX Lawsuit Alleges Company Allegedly Violated Drug Promotion Laws - ImmunityBio Investors Face Losses Following Company Allegedly Violated Drug Promotion Laws: SueWallSt • PR Newswire (US) • 04/23/2026 01:00:00 PM
- IBRX Shareholder Alert: May 26, 2026 Lead Plaintiff Deadline in ImmunityBio, Inc. Securities Class Action Lawsuit -- The Gross Law Firm • PR Newswire (US) • 04/21/2026 01:00:00 PM
- ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership • Business Wire • 04/21/2026 11:30:00 AM
- ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX • PR Newswire (US) • 04/20/2026 07:09:00 AM
- IBRX Lawsuit Alleges Chairman Allegedly Concealed Drug Limitation Risks - ImmunityBio Investors Face Losses Following Chairman Allegedly Concealed Drug Limitation Risks: SueWallSt • PR Newswire (US) • 04/16/2026 01:00:00 PM
